Finally Use Case 4 focuses on predicting cardiac complications due to hepatocellular carcinoma (HCC) treatments, for well-established therapies at different stages (e.g. partial hepatectomy or transplantation in early stages; Transarterial Chemoembolization (TACE) as a
first-line therapy in intermediate stage;​ immunotherapies or Tyrosine kinase inhibitors (TKIs) as systematic therapy for advanced stage).